Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

IMMU-114 will be studied at different dose schedules and dose levels in order to assess the highest dose safely tolerated. IMMU-114 will be administered subcutaneously (under the skin). IMMU-114 will be given 1-2 times weekly for 3 weeks followed by one week of rest. This is considered one cycle. Treatment cycles will be repeated until toxicity or worsening of disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

NCT01585688

Non-Hodgkin's Lymphoma Chronic Lymphocytic Leukemia

TERMINATED PHASE1/PHASE2

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

NCT05144347

Non-Hodgkin's Lymphoma (NHL) Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL) Mantle Cell Lymphoma (MCL) +2 more

TERMINATED PHASE1

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

NCT04746131

B-cell Non-Hodgkin's Lymphoma

SUSPENDED PHASE1

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

NCT02109224

Adult B Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia Cutaneous B-Cell Non-Hodgkin Lymphoma +26 more

TERMINATED PHASE1

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

NCT05014412

Multiple Myeloma

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-hodgkin's Lymphoma Follicular Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IMMU-114

IMMU-114 will be administered subcutaneously (under the skin) once or twice weekly for 3 weeks followed by one week of rest. Treatment cycles will continue until disease worsening or toxicity. Various dose levels will be studied.

Group Type EXPERIMENTAL

IMMU-114

Intervention Type DRUG

hL243 is a humanized antibody that targets HLA-DR, which is found on various b-cell hematologic malignancies and in autoimmune diseases.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IMMU-114

hL243 is a humanized antibody that targets HLA-DR, which is found on various b-cell hematologic malignancies and in autoimmune diseases.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

hL243

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have met the diagnostic criteria for CLL/SLL according to the IWCLL 2008 \[13\] or WHO Guidelines at some point during their disease course:
* Patients with SLL: tumor biopsy immunohistochemistry diagnostic of SLL or blood/bone marrow immunophenotype similar to CLL without lymphocytosis and enlarged lymph nodes.
* Patient must have relapsed or refractory CLL/SLL following at least one purine analog-containing regimen (or after one non-purine analog containing regimen if there is a relative contraindication to purine-analog containing therapy) and not have traditional options available or decline these. Patients with prolymphocytic leukemia (PLL)-CLL or PLL transformation of CLL are eligible.
* Patients must meet IWCLL 2008 Guideline \[13\] criteria for active disease requiring treatment.

* Patients with histologically confirmed B-cell NHL including marginal zone lymphoma, follicular lymphoma, or mantle cell lymphoma by WHO criteria.
* Patients must have relapsed or refractory disease after at least one prior therapy and not have traditional options available or decline these.

* Age ≥ 18 years
* Able to understand and sign a written informed consent document.
* Able to receive outpatient treatment and follow-up at the treating institution.
* ECOG performance status 0-1.
* Relapsed/refractory to at least one prior standard systemic treatment regimen, but no more than 4.
* Completed all prior therapies (immunosuppressive medications, antineoplastic therapy, vaccination, immunotherapy, chemotherapy, radiotherapy, major surgery, etc) \>4 weeks prior to the first study dose of medication (alemtuzumab ≥ 6 months).
* If receiving corticosteroids, ≤ 20 mg/day prednisone or equivalent and unchanged
* Patients capable of reproduction and male patients who have partners capable of reproduction must agree to use an effective contraceptive method during the course of the study and for 2 months following the completion of their last treatment.
* Females of childbearing potential must have a negative serum β-Hcg pregnancy test result within 7 days of first study dose. Female patients who are surgically sterilized or who are \> 45 years old and have not experienced menses for \> 2 years may have β- Hcg pregnancy test waived.
* Required baseline laboratory data
* Platelet count ≥ 75,000/mm3
* Absolute neutrophil count (ANC) ≥ 1500/mm3
* AST/ALT ≤ 2.5 times upper limit of normal (ULN)
* Creatinine and total bilirubin ≤ 1.5 times ULN

Exclusion Criteria

* Patients having received anti-CD20 therapy ≤ 4 weeks prior to the first study dose.
* Patients having received alemtuzumab (anti-CD52) therapy ≤ 6 months prior to the first study dose.
* Patients having undergone prior allogeneic stem cell transplantation within 6 months or having active graft versus host disease.
* Patients with active Richter's syndrome (\>10% large B-cells in marrow).
* Patients that have been designated Class III or IV by the New York Heart Association Functional Classification.
* Patients with a history of myocardial infarction or stroke within the last 6 months
* Patients with transfusion-dependent anemia.
* Patients with known hypersensitivity to any excipient contained in the drug formulation.
* Patients with a history of documented human anti-globulin antibodies.
* Patients with active viral, bacterial or systemic fungal infection requiring treatment.
* Patients who are known to be HIV or hepatitis C positive.
* Patients with a history of prior secondary malignancy that requires active systemic therapy that will interfere with interpretation of efficacy or toxicity of IMMU-114, or limit survival to 2 years. These patients should be discussed with the sponsor prior to enrollment. Patients with basal or squamous skin carcinoma, cervical carcinoma in situ on biopsy, localized breast cancer requiring hormonal therapy or localized prostate cancer (Gleason score \< 5) do not require discussion.
* Patients with active known CNS lymphoma. Patients with history of CNS leukemia now in remission are eligible for the trial.
* Patients who are pregnant or breast-feeding.
* Patients with major surgery or radiation therapy within 4 weeks prior to first study dose.
* Patients must have recovered all toxicities from prior therapy or radiation to grade 1 or less (excluding alopecia).
* Patients with substance abuse or other medical or psychiatric conditions that, in the opinion of the investigator, would confound study interpretation or affect the patient's ability to tolerate or complete the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No